Why the study?
Does intravenous injection of apoA-V rHDL reduce plasma triglyceride concentration in genetically engineered mouse models of severe hypertriglyceridemia?
Population
Genetically engineered mouse models of severe hypertriglyceridemia, including apoav-/- and gpihbp1-/- mice
Design
Preclinical
Follow-up
4 hours
Authors
Loading...
ApoA-V rHDL may lower TG in apoA-V deficiency; hypothesis-generating for human severe hypertriglyceridemia.
Does intravenous injection of apoA-V rHDL reduce plasma triglyceride concentration in genetically engineered mouse models of severe hypertriglyceridemia?
Intravenous apoA-V rHDL significantly lowers plasma triglycerides in apoA-V deficient mice, suggesting potential therapeutic utility for severe hypertriglyceridemia.
Shu et al. (2010) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: